PIPELINE
For a better future SCM Lifescience will do its best
CoImmune Pipeline
Pipeline
pipeline
preclinical
Phase 1
clinical trial
clinical trial
Phase 2
clinical trial
clinical trial
Phase 3
clinical trial
clinical trial
Acute Lymphocytic Leukemia
Metastatic Kidney Cancer
Non-Hodgkins Lymphoma
Chronic Lymphocytic Leukemia
Colmmune is not our subsidiary company, but a company we invested in.
The purpose of this section is just to introduce the pipeline of Colmmune.
Acute lymphocytic leukemia
Proven allogeneic, virus-free CARCIK - CD19 therapy
Primary endpoint : Dose-limiting toxicity: Assessment of the frequency and severity of cytokine release syndrome over a 1-month period
Secondary endpoints : Over all Response Rate (ORR), etc.
-
IndicationAcute lymphocytic leukemia
(All)
-
Number of patients21 people
For children and adults
-
Dosing regimenSTAETING DOSETREATMENT DOSECARCIK - CD19DL1*DL2DL3DL4Dosage1 X 1063 X 1067.5 X 10615 X 106
-
Designopen label, single group, dose escalation test
clinical trial institution
Limitations of Autologous CAR-T Therapeutics
- 01
high cost of treatment
- 02
cytokine release syndrome
- 03
Logistics difficulties due to self-treatment
Competitiveness of CAR-CIK
- 01
low cost of treatment
- 02
low cytokine release syndrome
- 03
high efficacy
Sleeping beauty transfer factor system
Utilizing cytokine-induced killer cell technology